Edition:
United Kingdom

Emergent BioSolutions Inc (EBS.N)

EBS.N on New York Stock Exchange

48.51USD
5:36pm GMT
Change (% chg)

$0.97 (+2.04%)
Prev Close
$47.54
Open
$48.16
Day's High
$49.77
Day's Low
$48.16
Volume
41,726
Avg. Vol
111,426
52-wk High
$49.77
52-wk Low
$27.94

Select another date:

Mon, Jan 8 2018

BRIEF-Emergent Biosolutions Sees FY 2017 Revenue $555 Million To $560 Million

* EMERGENT BIOSOLUTIONS ANNOUNCES PRELIMINARY 2017 FINANCIAL RESULTS AND PROVIDES 2018 FINANCIAL OUTLOOK

BRIEF-Emergent Biosolutions reports third quarter results

* Emergent Biosolutions reports third quarter and nine months 2017 financial results; raises calendar year 2017 guidance

BRIEF-Emergent Biosolutions awarded U.S. Department of State contract valued at up to $25 mln to supply nerve agent antidote auto-injector

* Emergent Biosolutions awarded U.S. Department of State contract valued at up to $25 million to supply nerve agent antidote auto-injector

BRIEF-Emergent Biosolutions completes acquisition of Raxibacumab from GSK​

* Emergent Biosolutions Inc - ‍transaction anticipated to be additive by approximately $9 million to revenue and neutral to GAAP net income for full year 2017​

BRIEF-Emergent BioSolutions signs five-year follow-on contract with DoD valued at up to $171 mln​

* Emergent BioSolutions to supply DoD with chemical threat countermeasure RSDL under five-year follow-on contract valued at up to $171 million

BRIEF-Emergent BioSolutions awarded $63 mln BARDA contract to develop treatment for cyanide exposure

* Emergent BioSolutions - awarded contract valued at about $63 mln by Biomedical Advanced Research And Development Authority

BRIEF-Emergent Biosolutions Q2 earnings per share $0.11

* Emergent Biosolutions reports second quarter and six months 2017 financial results; reaffirms calendar year 2017 guidance

BRIEF-Emergent Biosolutions awarded $23 mln to develop novel multi-drug auto-injector for U.S. Department Of Defense

* Emergent Biosolutions awarded $23 million to develop novel multi-drug auto-injector for U.S. Department of defense Source text for Eikon: Further company coverage:

BRIEF-Emergent Biosolutions Inc - ‍announced a licensing agreement with Valneva SE for global exclusive rights to Valneva's zika vaccine technology, ZIKV​

* Emergent Biosolutions Inc - ‍announced a licensing agreement with Valneva SE for global exclusive rights to Valneva's zika vaccine technology, ZIKV​

BRIEF-Emergent Biosolutions to acquire Raxibacumab from GSK

* Emergent Biosolutions to acquire Raxibacumab, an FDA-approved Anthrax monoclonal antibody, from GSK

Select another date: